Insurance Denied Psoriasis Treatment? How to Appeal Biologic Denials for Taltz, Cosentyx, and Skyrizi

Plaque psoriasis affects approximately 7.5 million Americans and can be a devastating, disfiguring, and painful condition. For patients with moderate-to-severe psoriasis who haven't responded to topical treatments or conventional systemic therapy, biologics like Taltz (ixekizumab), Cosentyx (secukinumab), Skyrizi (risankizumab), Tremfya (guselkumab), and Otezla (apremilast) offer transformative results. Insurers routinely deny these treatments through step therapy mandates and overly restrictive medical necessity criteria — but these denials are frequently overturnable.

Why Insurers Deny Psoriasis Biologics

• Step therapy mandates: Insurers require failure of conventional systemic therapies — methotrexate, cyclosporine, or acitretin — before approving biologics, even when these older drugs carry significant toxicities
• BSA threshold: Insurers set a body surface area threshold (e.g., >10% BSA) ignoring that even limited BSA psoriasis on the face, hands, feet, or genitals can be severely disabling
• PASI score threshold: Some insurers require a minimum PASI score even though the AAD recognizes PASI alone doesn't capture full disease burden
• Non-preferred biologic substitution: Insurer approves a different biologic without accounting for mechanism differences (e.g., IL-23 inhibitor vs. TNF inhibitor)

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered charge), B15 (authorization required).

How to Appeal a Psoriasis Biologic Denial

Step 1: Document Disease Severity Comprehensively

Dermatologist notes should include ICD-10 L40.0 (Psoriasis vulgaris), PASI score at baseline, BSA with specific affected locations noted (including difficult-to-treat areas), DLQI (Dermatology Life Quality Index) score, and all prior treatments tried with outcomes. A DLQI score above 10 indicates severe quality-of-life impact. When psoriasis affects the face, scalp, nails, palms, soles, or genitals, even BSA below 10% can be profoundly disabling — document these locations explicitly.

Step 2: Cite AAD Clinical Practice Guidelines

The American Academy of Dermatology (AAD) 2019 Clinical Practice Guidelines for the Management of Psoriasis with Biologics state that biologic therapy is appropriate for moderate-to-severe psoriasis unresponsive to topical therapy, that "moderate-to-severe" is not defined solely by BSA, and that IL-17 inhibitors (Cosentyx, Taltz) and IL-23 inhibitors (Skyrizi, Tremfya) have demonstrated superior efficacy to anti-TNF agents in head-to-head trials. Cite these guidelines directly with publication details.

Step 3: Challenge Step Therapy Requirements

Your physician's letter should list all prior therapies with doses, durations, and reasons for discontinuation, invoke your state's step therapy exception law if prior therapy was tried or contraindicated, and explain why the requested biologic is preferable based on mechanism and published evidence. Methotrexate carries hepatotoxicity risk; cyclosporine carries nephrotoxicity and hypertension risk — these are meaningful contraindications to step therapy requirements.

Step 4: Make the Comorbidity Argument

Psoriasis is associated with psoriatic arthritis (affecting 10–30% of psoriasis patients) and elevated cardiovascular disease risk. If psoriatic arthritis is present (ICD-10 L40.5x series), biologic therapy treats both conditions simultaneously — denying the biologic fails to treat active joint disease. Include rheumatologist documentation if applicable. The National Psoriasis Foundation (NPF) Treat to Target recommendations define treatment goals as PASI 75 or achieving PASI ≤2 and BSA ≤1%.

Step 5: Request External Independent Review: Complete Guide" class="auto-link">External Review with Dermatology Expertise

Dermatology has clear, evidence-based guidelines. Request an external IMR ensuring the reviewer has dermatology expertise. Independent reviewers regularly overturn biologic denials that conflict with AAD standards.

Step 6: Check FDA-Approval Status

All major psoriasis biologics are FDA-approved: Cosentyx (2015), Taltz (2016), Tremfya (2017), Skyrizi (2019), Otezla (2014). The insurer cannot classify an FDA-approved drug as experimental or deny on grounds of inadequate evidence when the FDA has already reviewed and approved the evidence.

What to Include in Your Appeal

• Dermatologist notes with PASI, BSA (including location documentation for difficult-to-treat areas), and DLQI scores
• AAD 2019 Clinical Practice Guidelines citation supporting biologic therapy for the patient's clinical situation
• State step therapy exception law citation if prior therapies were tried or are contraindicated
• Rheumatologist documentation if psoriatic arthritis is present, invoking dual-indication coverage
• FDA approval documentation for the requested biologic with approval date

Fight Back With ClaimBack

Psoriasis is visible, painful, and socially isolating — and you deserve access to the treatments your dermatologist recommends. Biologic denials that conflict with AAD guidelines and PASI/BSA documentation are frequently overturned. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal